Infliximab biosimilar (Ospedale San Raffaele)

英夫利西单抗生物类似药 (Ospedale San Raffaele)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfliximab biosimilar (Ospedale San Raffaele)

Drug Alias Name英夫利西单抗生物仿制药 (Ospedale San Raffaele)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsTakayasu Arteritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsTakayasu Arteritis

Inactive IndicationsN/A

ATC CodeL04AB02